Tourmaline Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Tourmaline Bio Inc expected to post a loss of 94 cents a share - Earnings Preview
Brief: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial
Brief: Tourmaline Bio Reports First Quarter 2025 Financial Results
Tourmaline Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Tourmaline Bio Inc expected to post a loss of 88 cents a share - Earnings Preview
Brief: Tourmaline Bio's cash position to provide cash runway into second half of 2027
Brief: Tourmaline Bio Inc Files For Mixed Shelf Of Up To $350 Million - SEC Filing
Tourmaline Bio Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Tourmaline Bio Presents Phase 2 Tranquility Study Design At American Society Of Preventive Cardiology Congress 2024
Brief: Tourmaline Bio Announces The Promotion Of Ryan Robinson To Chief Financial Officer
Brief: Tourmaline Bio Initiates Clinical Development Of TOUR006 For Cardiovascular Diseases
Tourmaline Bio Inc reports results for the quarter ended in March - Earnings Summary
Immunovant and Argenx rise as rival Chugai's data fails to impress
U.S. RESEARCH ROUNDUP-Adobe, Microsoft, ServiceNow
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Tourmaline Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Pfizer Inc Reports Passive Stake Of 4.96% In Tourmaline Bio Inc As Of Jan 29
U.S. STOCKS ON THE MOVE-Humana, Boeing, Tesla